Steven W. Yancey

12.2k total citations · 5 hit papers
122 papers, 8.2k citations indexed

About

Steven W. Yancey is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Steven W. Yancey has authored 122 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Physiology, 74 papers in Pulmonary and Respiratory Medicine and 40 papers in Surgery. Recurrent topics in Steven W. Yancey's work include Asthma and respiratory diseases (99 papers), Respiratory and Cough-Related Research (55 papers) and Eosinophilic Esophagitis (39 papers). Steven W. Yancey is often cited by papers focused on Asthma and respiratory diseases (99 papers), Respiratory and Cough-Related Research (55 papers) and Eosinophilic Esophagitis (39 papers). Steven W. Yancey collaborates with scholars based in United States, United Kingdom and France. Steven W. Yancey's co-authors include Héctor Ortega, Ian Pavord, Oliver N. Keene, Eugene R. Bleecker, Pascal Chanez, Harold S. Nelson, Lynn E. Katz, Paul Dorinsky, Mark C. Liu and Charlene M. Prazma and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Steven W. Yancey

115 papers receiving 7.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

2014 1.6k citations Héctor Ortega, Ian Pavord et al. profile →
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

2014 1.2k citations Elisabeth H. Bel, Charlene M. Prazma et al. profile →
The Salmeterol Multicenter Asthma Research Trial

2006 749 citations Harold S. Nelson, Eugene R. Bleecker et al. CHEST Journal profile →
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

2016 396 citations Héctor Ortega, Steven W. Yancey et al. The Lancet Respiratory Medicine profile →
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

2017 384 citations Ian Pavord, Pascal Chanez et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven W. Yancey United States	35	7.0k	5.7k	1.3k	1.3k	1.2k	122	8.2k
Héctor Ortega United States	37	7.1k 1.0×	5.4k 0.9×	1.5k 1.1×	2.0k 1.5×	1.8k 1.5×	117	8.6k
Roland Buhl Germany	32	4.3k 0.6×	3.6k 0.6×	1.0k 0.8×	680 0.5×	1.0k 0.8×	148	5.5k
Ruth H. Green United Kingdom	22	5.5k 0.8×	4.2k 0.7×	958 0.7×	808 0.6×	1.6k 1.3×	32	6.5k
Jonathan Corren United States	44	9.0k 1.3×	5.2k 0.9×	4.6k 3.5×	1.4k 1.1×	2.6k 2.1×	225	11.0k
Wendy C. Moore United States	39	4.1k 0.6×	3.0k 0.5×	626 0.5×	689 0.5×	1.4k 1.2×	98	5.5k
David S. Pearlman United States	39	4.3k 0.6×	3.1k 0.5×	1.7k 1.3×	388 0.3×	734 0.6×	121	5.4k
Njira Lugogo United States	28	2.5k 0.4×	2.1k 0.4×	458 0.3×	469 0.4×	735 0.6×	160	3.9k
Mina Gaga Greece	39	2.8k 0.4×	2.1k 0.4×	1.6k 1.2×	316 0.2×	949 0.8×	120	5.1k
Stephen C. Lazarus United States	37	3.5k 0.5×	3.1k 0.5×	675 0.5×	330 0.3×	1.1k 0.9×	108	5.3k
Pierluigi Paggiaro Italy	29	2.8k 0.4×	2.4k 0.4×	571 0.4×	262 0.2×	442 0.4×	101	3.7k

Countries citing papers authored by Steven W. Yancey

Since Specialization

Citations

This map shows the geographic impact of Steven W. Yancey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven W. Yancey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven W. Yancey more than expected).

Fields of papers citing papers by Steven W. Yancey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven W. Yancey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven W. Yancey. The network helps show where Steven W. Yancey may publish in the future.

Co-authorship network of co-authors of Steven W. Yancey

This figure shows the co-authorship network connecting the top 25 collaborators of Steven W. Yancey. A scholar is included among the top collaborators of Steven W. Yancey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven W. Yancey. Steven W. Yancey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pavord, Ian, Roland Buhl, Monica Kraft, et al.. (2022). Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. ERJ Open Research. 8(2). 560–2021. 11 indexed citations

Borish, Larry, Noah Cohen, Geoffrey Chupp, et al.. (2022). Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. Annals of Allergy Asthma & Immunology. 129(2). 160–168. 17 indexed citations

Pane, Fabrizio, Guillaume Lefèvre, Namhee Kwon, et al.. (2022). Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome. Frontiers in Immunology. 13. 935996–935996. 4 indexed citations

Gevaert, Philippe, Joseph K. Han, Steven G. Smith, et al.. (2022). The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. International Forum of Allergy & Rhinology. 12(11). 1413–1423. 73 indexed citations

Pavord, Ian, Kenneth R. Chapman, Mona Bafadhel, et al.. (2021). Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International Journal of COPD. Volume 16. 1755–1770. 52 indexed citations

Yancey, Steven W., Eric Bradford, & Oliver N. Keene. (2019). Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150–300 cells/μL. Respiratory Medicine. 151. 139–141. 9 indexed citations

Prazma, Charlene M., et al.. (2019). Mepolizumab improves patient outcomes and reduces exacerbations in severe asthma patients with comorbid upper airways disease. Journal of Allergy and Clinical Immunology. 143(2). AB94–AB94. 7 indexed citations

Albers, Frank C., Alberto Papi, Camille Taillé, et al.. (2019). Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respiratory Research. 20(1). 169–169. 38 indexed citations

Menzies‐Gow, Andrew, Mark Forshag, Frank C. Albers, et al.. (2018). Improvement of lung function measured by AM PEF in patients with severe eosinophilic asthma treated with mepolizumab: A combined analysis of the MENSA and MUSCA studies. Journal of Allergy and Clinical Immunology. 141(2). AB16–AB16. 1 indexed citations

10.

Chapman, Kenneth R., Ian Pavord, Pierluigi Paggiaro, et al.. (2018). Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function. American Journal of Respiratory and Critical Care Medicine. 197. 2 indexed citations

11.

Nelsen, Linda, Margaret Vernon, Héctor Ortega, et al.. (2017). Evaluation of the psychometric properties of the St George's Respiratory Questionnaire in patients with severe asthma. Respiratory Medicine. 128. 42–49. 8 indexed citations

12.

Prazma, Charlene M., Elisabeth H. Bel, Neil Barnes, et al.. (2016). Steroid Sparing Response with Mepolizumab: Durability of Steroid Reduction in Severe Asthma. Journal of Allergy and Clinical Immunology. 137(2). AB16–AB16. 4 indexed citations

13.

Ortega, Héctor, Steven W. Yancey, Bhabita Mayer, et al.. (2016). Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. The Lancet Respiratory Medicine. 4(7). 549–556. 396 indexed citations breakdown →

14.

Lugogo, Njira, Christian Domingo, Pascal Chanez, et al.. (2016). Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clinical Therapeutics. 38(9). 2058–2070.e1. 219 indexed citations

15.

Ortega, Héctor, Mark Liu, Ian Pavord, et al.. (2014). Late-breaking abstract: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. European Respiratory Journal. 44(Suppl 58). 2906–2906. 1 indexed citations

16.

Bleecker, Eugene R., Harold S. Nelson, Monica Kraft, et al.. (2009). β2-Receptor Polymorphisms in Patients Receiving Salmeterol with or without Fluticasone Propionate. American Journal of Respiratory and Critical Care Medicine. 181(7). 676–687. 81 indexed citations

17.

Kerwin, Edward, Robert A. Nathan, Eli O. Meltzer, et al.. (2008). Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily. Respiratory Medicine. 102(4). 495–504. 11 indexed citations

18.

Nathan, Robert A., Steven W. Yancey, Barbara A. Prillaman, et al.. (2005). Fluticasone Propionate Nasal Spray Is Superior to Montelukast for Allergic Rhinitis While Neither Affects Overall Asthma Control. CHEST Journal. 128(4). 1910–1920. 32 indexed citations

19.

Nelson, Harold S., et al.. (1999). Lack of Subsensitivity to Albuterol After Treatment with Salmeterol in Patients with Asthma. American Journal of Respiratory and Critical Care Medicine. 159(5). 1556–1561. 47 indexed citations

20.

Grossfeld, Robert M., Steven W. Yancey, & Claude F. Baxter. (1984). Inhibitors of crayfish glutamic acid decarboxylase. Neurochemical Research. 9(7). 947–963. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact